Moleculin Biotech (NASDAQ:MBRX) Stock Passes Below 50 Day Moving Average – Time to Sell?

Moleculin Biotech, Inc. (NASDAQ:MBRX) crossed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $1.21 and traded as low as $0.7735. Moleculin Biotech shares last traded at $0.8299, with a volume of 531,906 shares trading hands.

Analyst Ratings Changes

MBRX has been the topic of several research reports. Weiss Ratings restated a “sell (e+)” rating on shares of Moleculin Biotech in a report on Friday, July 17th. Wall Street Zen upgraded Moleculin Biotech from a “strong sell” rating to a “sell” rating in a report on Saturday, August 15th. Finally, HC Wainwright dropped their price target on Moleculin Biotech to $3.00 and set a “buy” rating on the stock in a research report on Friday, August 28th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $3.00.

Moleculin Biotech Trading Down 13.8%

The firm’s 50-day moving average price is $1.17 and its two-hundred day moving average price is $2.01. The stock has a market cap of $13.93 million, a PE ratio of -0.10 and a beta of 1.92.

Moleculin Biotech (NASDAQ:MBRX) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($1.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.55) by $0.15. On average, analysts anticipate that Moleculin Biotech, Inc. will post -2.37 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Moleculin Biotech stock. Jane Street Group LLC acquired a new position in shares of Moleculin Biotech, Inc. (NASDAQ:MBRX) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned about 1.11% of Moleculin Biotech at the end of the most recent reporting period. Hedge funds and other institutional investors own 15.52% of the company’s stock.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.